...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Preventive Medicine: An International Journal Devoted to Practice and Theory >Comparative cost effectiveness of varicella, hepatitis A, and pneumococcal conjugate vaccines.
【24h】

Comparative cost effectiveness of varicella, hepatitis A, and pneumococcal conjugate vaccines.

机译：水痘，甲型肝炎和肺炎球菌结合疫苗的成本效益比较。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BACKGROUND: Several state and local U.S. governments are considering making varicella, hepatitis A, and/or pneumococcal conjugate vaccination conditions of day care or school entry. These requirements will likely be issued sequentially, because simultaneous mandates exacerbate budget constraints and complicate communication with parents and providers. Cost-effectiveness assessments should aid the establishment of vaccination priorities, but comparing results of published studies is confounded by their dissimilar methods. METHODS: We reviewed U.S. cost-effectiveness studies of childhood varicella, hepatitis A, and pneumococcal conjugate vaccines and identified four providing data required to standardize methods. Vaccination, disease treatment, and work-loss costs were estimated from original study results and current prices. Estimated life-years saved were derived from original study results, epidemiological evidence, and alternative procedures for discounting to present values. RESULTS: Hepatitis A vaccine would have the lowest health system costs per life-year saved. Varicella vaccine would provide the greatest reduction in societal costs, mainly through reduced parent work loss. Pneumococcal conjugate vaccine would cost twice the amount of varicella and hepatitis A vaccines combined and be less cost effective than the other vaccines. CONCLUSIONS: Hepatitis A and varicella vaccines, but not pneumococcal conjugate vaccine, meet or exceed conventional standards of cost effectiveness.
机译：背景：美国几个州和地方政府正在考虑制定日托或入学的水痘，甲型肝炎和/或肺炎球菌结合疫苗接种条件。这些要求可能会按顺序发布，因为同时执行任务会加重预算限制，并使与父母和提供者的沟通变得复杂。成本效益评估应有助于确定疫苗接种的优先顺序，但比较已发表研究的结果却因其方法不同而感到困惑。方法：我们回顾了美国关于儿童水痘，甲型肝炎和肺炎球菌结合疫苗的成本效益研究，并确定了四种提供标准化方法所需的数据。疫苗接种，疾病治疗和工作损失成本是根据原始研究结果和当前价格估算的。估计的挽救生命年数来自原始研究结果，流行病学证据以及折现值的替代程序。结果：甲型肝炎疫苗每生命年可节省的卫生系统成本最低。水痘疫苗将最大程度地降低社会成本，主要是通过减少父母工作损失。肺炎球菌结合疫苗的成本是水痘和甲型肝炎疫苗总和的两倍，且成本效益比其他疫苗低。结论：甲型肝炎和水痘疫苗，但不是肺炎球菌结合疫苗，达到或超过了常规的成本效益标准。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号